Bernstein reiterates Merck stock rating on KRAS deal activity

Bernstein SocGen Group maintained a Market Perform rating and set a price target of $105.00 for Merck (NYSE:MRK) shares, following the pharmaceutical company's licensing agreement involving a KRAS inhibitor. Merck, boasting a market capitalization of $366.6 billion, has experienced a remarkable 95% return over the past year; however, its shares are currently trading at $148.36, 5% below their 52-week high of $156.92.

The company announced a licensing deal with private firm SciBrunch for an investigational preclinical oral KRAS G12D inhibitor, named SPR2015. This exclusive, global license covers the early-stage compound targeting the G12D mutation, including a $400 million upfront payment as part of a potential deal value of up to $2.13 billion.

This upfront payment represents 19% of the total deal value, far exceeding the typical 5% to 10% range for preclinical licenses. Bernstein analyst Courtney Breen pointed out that this acquisition may eliminate potential deals between Merck and competitors like Revolution Medicines or Erasca, making the deal particularly robust mechanistically.

As KRAS competition intensifies, the impact of on-only mechanisms versus on/off mechanisms on the market for pancreatic and lung cancer treatments remains to be seen. According to InvestingPro analysis, Merck's stock currently trades slightly above its Fair Value, positioning the company as a significant player in the Pharmaceuticals industry.

Investors interested in a more detailed analysis can access Merck's comprehensive Pro Research Report, one of over 1,400 available reports that turn complex data into actionable intelligence.